ARGX 110

Drug Profile

ARGX 110

Alternative Names: Anti-CD70 SIMPLE Antibody; ARGX-110

Latest Information Update: 12 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator arGEN-X
  • Developer argenx
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD70 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T cell lymphoma
  • Phase I/II Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes; Solid tumours
  • Phase I Nasopharyngeal cancer
  • Preclinical Autoimmune disorders

Most Recent Events

  • 01 Mar 2018 argenx plans a phase II proof-of-concept trial for Acute myeloid leukemia before end of 2018
  • 12 Dec 2017 Interim efficacy data from a phase I/II trial in Haematological malignancies and Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) released by argenx
  • 11 Dec 2017 Interim efficacy data from a phase II trial in Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy, First-line therapy) released by argenx
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top